Validation & Stability Indicating RP-HPLC Method for Meloxicam Capsule

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3carboxamide-1,1 -dioxide) is an NSAID used in the management of rheumatic disease, which is distinguished by the fact that it is well tolerated by the stomach at the doses necessary for therapy. The anti-inflammatory and pain-relieving properties of Meloxicam make this active substance very interesting for use in pain therapy. Meloxicam act as nonselective inhibitor of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. A rapid, specific isocratic RP-HPLC method has been developed for the determination of Meloxicam capsules using a UV/diode array detector. The method was validated as per ICH guidelines and USP/NF. Therefore, this method can be useful for routine analysis of Meloxicam capsules as bulk drug and dosage form.